Toru Naganuma

Showing 1-9 of 9 articles

Silent Valsalva thrombus between the native Valsalva and balloon-expandable transcatheter heart valve: multicentre Japanese registry analysis

Tsunaki T, Yamamoto M, Shimura T, Kagase A, Naganuma T, Higashimori A, Araki M, Yamanaka F, Mizutani K, Watanabe Y, Otsuka T, Yanagisawa R, Hayashida K

November 15, 2019 | 10.4244/EIJ-D-19-00370

Coronary interventions

Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score

Ortega-Paz L, Capodanno D, Gori T, Nef H, Latib A, Caramanno G, Di Mario C, Naber C, Lesiak M, Capranzano P, Wiebe J, Mehilli J, Araszkiewicz A, Pyxaras S, Mattesini A, Geraci S, Naganuma T, Colombo A, Münzel T, Sabaté M, Tamburino C, Brugaletta S

April 20, 2017 | 10.4244/EIJ-D-16-00974

Coronary interventions

Clinical outcomes of a real-world cohort following bioresorbable vascular scaffold implantation utilising an optimised implantation strategy

Tanaka A, Latib A, Kawamoto H, Jabbour R, Sato K, Miyazaki T, Naganuma T, Mangieri A, Pagnesi M, Montalto C, Chieffo A, Carlino M, Montorfano M, Colombo A

February 20, 2017 | 10.4244/EIJ-D-16-00247

Coronary interventions

Procedural outcomes of patients with calcified lesions treated with bioresorbable vascular scaffolds

Panoulas V, Miyazaki T, Sato K, Naganuma T, Sticchi A, Kawamoto H, Figini F, Chieffo A, Carlino M, Montorfano M, Latib A, Colombo A

March 18, 2016 | 10.4244/EIJY15M03_11

Coronary interventions

Drug-eluting balloon versus second-generation drug-eluting stent for the treatment of restenotic lesions involving coronary bifurcations

Naganuma T, Latib A, Costopoulos C, Oreglia J, Testa L, De Marco F, Candreva A, Chieffo A, Naim C, Montorfano M, Bedogni F, Colombo A

January 20, 2016 | 10.4244/EIJY14M11_01

How should I treat multiple coronary aneurysms with severe stenoses?

Warisawa T, Naganuma T, Nakamura S

November 20, 2015 | 10.4244/EIJV11I7A171

Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry

Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, Caramanno G, Naber C, Di Mario C, Colombo A, Capranzano P, Wiebe J, Araszkiewicz A, Geraci S, Pyxaras S, Mattesini A, Naganuma T, Münzel T, Tamburino C

February 20, 2015 | 10.4244/EIJY14M07_11

Percutaneous intervention of calcific coronary lesions

Costopoulos C, Naganuma T, Colombo A

March 3, 2014

Tools and Techniques Clinical: Percutaneous intervention of calcific coronary lesions

Costopoulos C, Naganuma T, Colombo A

January 20, 2014 | 10.4244/EIJV9I9A188

1

Latest news

Trends and predictors of radiation exposure in percutaneous coronary intervention: the PROTECTION VIII study

FREE ARTICLE - Thomas J. Stocker et al

January 24, 2022

Three-year TAVI outcomes for BAV vs TAV

FREE ARTICLE - Dao Zhou et al.

January 20, 2022

EuroCTO Club Consensus on Dual Lumen Microcatheters for CTO Recanalisation; Predicting Radial Crossover in ACS, the MATRIX score; DAPT duration for BRS; and more…

December 17, 2021

Percutaneous management of left ventricular assist device outflow graft obstruction

FREE ARTICLE - Aleksandra Gasecka et al.

January 19, 2022

Lipid-rich plaque density and LDL-C in statin-treated vs statin-naïve patients

FREE ARTICLE - Rebecca Torguson et al.

January 17, 2022

Redo transcatheter mitral valve replacement in mitral annular calcification

FREE ARTICLE - Jennifer Jdaidani et al

January 13, 2022

TAVI vs SAVR in bicuspid aortic valve stenosis

FREE ARTICLE - Monil Majmundar et al.

January 12, 2022

Valvular disease